Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thioridazine for dementia.

V Kirchner1, C A Kelly, R J Harvey

  • 1Dementia Research Group, Institute of Neurology, The National Hospital for Neurology & Neurosurgery, Queen Square, London, UK, WC1N 3BG. r.harvey@dementia.ion.ucl.ac.uk

The Cochrane Database of Systematic Reviews
|November 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left-lateral laparotomy using a dorsoventral incision for unilateral ovariohysterectomy in free-ranging African lions (<i>Panthera leo</i>).

Journal of the South African Veterinary Association·2025
Same author

Operation Sahel: translocation and reintroduction of West African giraffe (<i>Giraffa camelopardalis peralta</i>) in Niger.

Journal of the South African Veterinary Association·2025
Same author

Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis.

Allergy·2024
Same author

Immobilisation protocols for wild giraffe <i>(Giraffa spp.)</i>- a review.

Journal of the South African Veterinary Association·2024
Same author

Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study.

Rhinology·2023
Same author

Protocolized screening and detection of occult alcohol use before and after liver transplant: Lessons learned from a quality improvement initiative.

Clinical transplantation·2023
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Thioridazine offers limited benefits for dementia patients, primarily reducing anxiety but showing no cognitive improvement. This phenothiazine neuroleptic has equal or higher adverse effects compared to placebo and other treatments, questioning its clinical utility.

Area of Science:

  • Geriatric Psychiatry
  • Pharmacology
  • Clinical Neurology

Background:

  • Neuroleptic drugs are controversial in dementia care, with emerging evidence suggesting they may accelerate clinical decline.
  • Thioridazine, a phenothiazine neuroleptic, is frequently prescribed for elderly patients with dementia due to perceived lower motor side effects and significant sedative properties.
  • Thioridazine possesses anticholinergic properties that may negatively impact cognitive function in dementia patients.

Purpose of the Study:

  • To evaluate the efficacy of thioridazine in dementia patients.
  • Assess thioridazine's effectiveness in symptom control, cognitive outcomes, and safety profile.

Main Methods:

  • A systematic literature search was conducted using terms 'thioridazine', 'melleril', 'dementia', and 'old age' across electronic databases and by contacting the manufacturer.

Related Experiment Videos

  • Included were unconfounded, single or double-blind, randomized trials comparing thioridazine to alternative interventions in dementia patients.
  • Data extraction focused on behavioral and cognitive outcomes, and adverse events; meta-analysis was performed using appropriate statistical methods like Peto odds ratio and weighted mean difference.

    • Main Results:

    • Thioridazine demonstrated a reduction in anxiety symptoms compared to placebo, but showed no significant effect on global clinical change.
    • Adverse effects were not significantly different from placebo, though a trend for higher incidence was noted. Dizziness was significantly more frequent compared to chlormethiazole.
    • Thioridazine showed no superiority over other neuroleptics (etoperidone, loxapine, zuclopenthixol) or diazepam, except for potentially fewer side effects than loxapine.

    Conclusions:

    • There is very limited evidence to support the use of thioridazine in dementia treatment; its introduction would not be supported by current data.
    • The primary observed benefit is anxiety reduction, but this is offset by equal or higher rates of adverse effects compared to placebo and other treatments.
    • Clinicians should be aware of the lack of evidence supporting thioridazine for dementia and the potential for increased side effects.